Prnewswire·2025-11-10 12:30Core Insights - ADC Therapeutics is advancing its clinical programs for ZYNLONTA, with updated data from LOTIS-7 expected by the end of 2025 and topline results from LOTIS-5 anticipated in the first half of 2026 [1][5][2] Financial Results - For Q3 2025, net product revenues were $15.8 million, a decrease from $18.0 million in Q3 2024. Year-to-date revenues were $51.2 million compared to $52.9 million for the same period in 2024 [4][19] - Research and Development (R&D) expenses for Q3 2025 were $26.8 million, down from $32.5 million in Q3 2024. Year-to-date R&D expenses increased to $85.8 million from $82.5 million in 2024 [4][19] - Selling and Marketing (S&M) expenses remained stable at $10.7 million for Q3 2025, with a slight decrease in year-to-date expenses to $31.4 million from $32.8 million in 2024 [4][19] - General and Administrative (G&A) expenses decreased to $8.3 million for Q3 2025 from $10.0 million in Q3 2024, and year-to-date G&A expenses were $27.1 million compared to $32.3 million in 2024 [4][19] - The net loss for Q3 2025 was $41.0 million, or $0.30 per share, an improvement from a net loss of $44.0 million, or $0.42 per share, in Q3 2024. Year-to-date net loss was $136.2 million, compared to $127.1 million in 2024 [4][19] Operational Updates - The company completed a $60 million PIPE financing, with net proceeds of approximately $57.6 million expected to fund the commercial expansion of ZYNLONTA [2][5] - Updated data from the Phase 2 investigator-initiated trial of ZYNLONTA in r/r follicular lymphoma showed an overall response rate of 98.2% and a complete response rate of 83.6% [5][4] - IND-enabling activities for a PSMA-targeting ADC are ongoing, with completion expected by the end of 2025 [5][4] Future Outlook - Multiple clinical catalysts are anticipated across LOTIS-7, LOTIS-5, and ongoing Phase 2 IITs, with the first data readout expected before the end of 2025 [2][5] - The company plans to engage with the FDA once sufficient data from LOTIS-7 is available, with potential regulatory submissions and approvals expected in 2027 [5][4]